Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Conditions: Multiple Sclerosis
Interventions: Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil; Other · Device · Dietary Supplement + 1 more
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions: estriol, Placebo, Norethindrone, Progestin Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more

Conditions: Multiple Sclerosis, Progressive
Interventions: Amniotic fluid or placental CD117 stem cells; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Co-formulated With rHuPH20; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Carlsbad, California • Maitland, Florida • Tampa, Florida + 3 more

Conditions: Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Kansas City, Kansas • St Louis, Missouri

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Idebenone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 37
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more

Conditions: Multiple Sclerosis
Interventions: gold nanocrystals; Drug
Lead sponsor: Clene Nanomedicine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: Not listed
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
Interventions: KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB; Biological · Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: ATA188, Placebo; Biological · Drug
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 22 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: DUOC-01; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions: Caprylic Triglyceride, Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions: Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: Emmanuelle Waubant, MD PhD; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Wellesley, Massachusetts • Cleveland, Ohio + 2 more

Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions: Intravenous and Intranasal BMSC; Procedure
Lead sponsor: MD Stem Cells; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Westport, Connecticut • Coral Springs, Florida

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more

Search by objective public record fields.

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Idebenone for Primary Progressive Multiple Sclerosis

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

MS-ResearchBiomarkerS

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

Metformin Treatment in Progressive Multiple Sclerosis

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

Neurologic Stem Cell Treatment Study

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)